Literature DB >> 12180145

Hypercholesterolemia in children with Smith-Magenis syndrome: del (17) (p11.2p11.2).

Ann C M Smith1, Andrea L Gropman, Joan E Bailey-Wilson, Ozlem Goker-Alpan, Sarah H Elsea, Jan Blancato, James R Lupski, Lorraine Potocki.   

Abstract

PURPOSE: Smith-Magenis syndrome (SMS), a probable contiguous gene syndrome due to an interstitial deletion of chromosome 17 band p11.2, is associated with a distinct and complex phenotype, including physical, developmental, and neurobehavioral features. The majority of SMS patients are deleted for a common approximately 4 Mb interval that includes the gene SREBF1, a transmembrane transcription factor that regulates the low density lipoprotein (LDL) receptor and plays a crucial role in cholesterol homeostasis. A systematic study of fasting lipid profiles of patients with SMS was conducted to determine the frequency of cholesterol abnormalities.
METHODS: Fasting lipid profiles were examined in 49 children (27F/22M) between the ages of 0.6 years to 17.6 years (mean, 6.9 years) with a cytogenetically confirmed diagnosis of SMS. Observed values for serum total cholesterol (TC), triglycerides (TG), LDL cholesterol, and high density lipoprotein cholesterol were compared with published norms. The body mass index (BMI) was used as a measure of nutritional status.
RESULTS: Mean TC was significantly higher than published NHANES III pediatric norms (P < 0.0008). Overall 28 of 49 (57%) SMS subjects had lipid values greater than the 95th percentile for age and gender for at least one or more of the following: TC, TG, and/or LDL. Only 16 SMS subjects (32%) were within normal limits for all three of these variables. BMI values showed minimal positive correlation to SMS lipid values; however, no consistent effect was found. Thus BMI values alone do not explain the marked trend in increased TC, TG, and/or LDL observed in the SMS group. Based on the American Academy of Pediatrics recommended lipid levels for children and adolescents, only one third of SMS subjects fall within normal range for TC and LDL; an additional one third each measure "borderline" or "high" for these values.
CONCLUSION: Hypercholesterolemia is common in SMS and may serve as a useful early clinical biochemical marker of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180145     DOI: 10.1097/00125817-200205000-00004

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  17 in total

Review 1.  CHD associated with syndromic diagnoses: peri-operative risk factors and early outcomes.

Authors:  Benjamin J Landis; David S Cooper; Robert B Hinton
Journal:  Cardiol Young       Date:  2015-09-08       Impact factor: 1.093

2.  Genetic counseling, activism and 'genotype-first' diagnosis of developmental disorders.

Authors:  Daniel Navon
Journal:  J Genet Couns       Date:  2012-07-21       Impact factor: 2.537

3.  RAI1 variations in Smith-Magenis syndrome patients without 17p11.2 deletions.

Authors:  S Girirajan; L J Elsas; K Devriendt; S H Elsea
Journal:  J Med Genet       Date:  2005-03-23       Impact factor: 6.318

4.  The Fragile X proteins Fmrp and Fxr2p cooperate to regulate glucose metabolism in mice.

Authors:  Jeannette G Lumaban; David L Nelson
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

5.  Mutations of RAI1, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome.

Authors:  Weimin Bi; G Mustafa Saifi; Christine J Shaw; Katherina Walz; Patricia Fonseca; Meredith Wilson; Lorraine Potocki; James R Lupski
Journal:  Hum Genet       Date:  2004-09-30       Impact factor: 4.132

6.  Molecular and Neural Functions of Rai1, the Causal Gene for Smith-Magenis Syndrome.

Authors:  Wei-Hsiang Huang; Casey J Guenthner; Jin Xu; Tiffany Nguyen; Lindsay A Schwarz; Alex W Wilkinson; Or Gozani; Howard Y Chang; Mehrdad Shamloo; Liqun Luo
Journal:  Neuron       Date:  2016-09-29       Impact factor: 17.173

7.  Modeling del(17)(p11.2p11.2) and dup(17)(p11.2p11.2) contiguous gene syndromes by chromosome engineering in mice: phenotypic consequences of gene dosage imbalance.

Authors:  Katherina Walz; Sandra Caratini-Rivera; Weimin Bi; Patricia Fonseca; Dena L Mansouri; Jennifer Lynch; Hannes Vogel; Jeffrey L Noebels; Allan Bradley; James R Lupski
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

8.  Smith-Magenis syndrome and growth hormone deficiency.

Authors:  Emanuela Spadoni; Patrizia Colapietro; Mauro Bozzola; Gian L Marseglia; Luciana Repossi; Cesare Danesino; Lidia Larizza; Paola Maraschio
Journal:  Eur J Pediatr       Date:  2004-05-08       Impact factor: 3.183

9.  Stroke after cardiac surgery in a patient with Smith-Magenis syndrome.

Authors:  Alyas P Chaudhry; Carl Schwartz; Arun K Singh
Journal:  Tex Heart Inst J       Date:  2007

10.  A duplication CNV that conveys traits reciprocal to metabolic syndrome and protects against diet-induced obesity in mice and men.

Authors:  Melanie Lacaria; Pradip Saha; Lorraine Potocki; Weimin Bi; Jiong Yan; Santhosh Girirajan; Brooke Burns; Sarah Elsea; Katherina Walz; Lawrence Chan; James R Lupski; Wenli Gu
Journal:  PLoS Genet       Date:  2012-05-24       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.